| Name | Title | Contact Details |
|---|
Bioclinica is the leader in scientifically-driven services and technology-enabled solutions in clinical research. Clinical trials are complex, and traditional approaches are either monolithic or fragmented. Successful trials require an ability to see key details and uncover hidden insights. Employing our scientifically-driven and technology-enabled approach, Bioclinica brings CLARITY to clinical trials for better decisions. With such clarity comes the insight to help trial sponsors and Clinical Research Organizations (CROs) develop new life-improving therapies more efficiently and safely ─ and with improved quality outcomes. Our scientific, medical, technology and domain expertise is unmatched and spans all major therapeutic areas ─ and the full trial lifecycle, from study protocol, to post-approval. Key offerings include: Medical imaging; Cardiac Safety; Clinical Adjudication; Randomization & Trial Supply Management and Optimization; Electronic and eSource Data Capture; Site Payments and Forecasting; Pharmacovigilance; Trial Management; and Risk-based Monitoring. Additionally, as a true multifaceted partner to trial sponsors and CROs, Bioclinica offers an integrated App xChange partner ecosystem, a global Research Network of investigative sites, Patient Recruitment and Lost to Follow-up Services, and Post-approval Research expertise. Bioclinica and our thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.
cenergyteam is a Sammamish, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lawrence Community Health Svc is a Tuckahoe, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CardioVention is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus`. The issued patents` extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.